Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Gold Falls Below $4,000 as Strong Dollar and Fed Rate Hike Expectations Weigh on Prices 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Why the future of marijuana legalization remains hazy despite high public support 
Asian Currencies Trade Mixed as Yen Hovers Near 40-Year Low, Dollar Holds Firm on Fed Outlook 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Oil Prices Drop as Middle East Supply Recovery Eases Market Concerns 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
CDC Monitors 41 Americans After Andes Hantavirus Outbreak on Luxury Cruise Ship 
U.S. Dollar Reaches One-Year High as Tech Sell-Off and Fed Rate Hike Expectations Support Demand 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
South Korean pharmaceutical and biotech companies are collaborating to develop new drugs using artificial intelligence (AI).
AI can predict whether a chemical compound is suitable for human use, thereby speeding up the identification of potential substances and enabling the selection of appropriate clinical patients.
There are over 100 cases where candidate substances for new drugs are under development using AI, with over 50 percent carried out through collaborations between domestic and foreign companies, according to the Korea Pharmaceutical and Bio-pharma Manufacturers Association.
HK inno.N Corp. and AinB recently signed an MOU to identify a new antibody candidate substance for cell and gene therapies and establish an antigen design platform for vaccine development.
Last year, Pharos iBio inked a deal with Yuhan Corp. to promote the joint study and technology transfer of the AI-based KRAS inhibitor.
This company is now carrying out a phase 1 clinical trial in Korea and Australia after developing PHI-101, a candidate substance for the treatment of leukemia, using its AI platform, Chemiverse.
Moreover, Oncocross, which has AI technology to identify the optimal disease for drugs, signed a joint study and development contract with Boryung Corp. in February to expand the indications of hypertension treatment.
